Objectives: The effect of anti-TNF therapy on the antibody responses to vaccines is subject of ongoing debate. Therefore, we investigated the effect of the three currently available anti-TNF agents on influenza vaccination outcomes in a patient population with longstanding disease.
Methods: In a prospective cohort study, we assessed the antibody response upon influenza vaccination in 112 patients with longstanding autoimmune disease treated with immunosuppressive medication either with anti-TNF (etanercept, adalimumab or infliximab; n=64) or without anti-TNF (n=48) and a control group of 18 healthy individuals. Antibody responses were determined by hemagglutination inhibition assay, before and four weeks after vaccination.
Results: The proportion of individuals with a protective titer (≥40) after vaccination was large (80 to 94%) and did not significantly differ between the three groups. Postvaccination geometric mean antibody titers against influenza (A/H3N2 and B) were significantly lower in the 64 patients treated with anti-TNF compared to the 48 patients not receiving anti-TNF and the healthy controls.
Conclusions: The antibody response to influenza vaccination in patients treated with anti-TNF is only modestly impaired. The proportion of patients that achieves a protective titer is not significantly diminished by the use of TNF blocking therapies
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.